|
||
Home -> Support -> Articles -> Brief Introduction of Recombinant AAV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quick Inquiry |
Brief Introduction of Recombinant AAV Wild type adeno associated viruses (wtAAVs) are small, non-enveloped viruses with a 4.7kb single-stranded DNA genome. Scientists have developed recombinant AAVs (rAAVs) as efficient transfer vectors that have been successfully utilized in many in vitro and in vivo applications. There is a set of unique characteristics which make rAAVs attractive as a genetic delivery vector. 1) Unlike human pathogenic HIV-derived recombinant lentiviruses (rLVs), wtAAVs are have not been reported to be associated with any human diseases. The engineered rAAVs are safer for researchers or end users. 2) Although wtAAVs can integrate into human chromosome 19 at the locus known as AAVS1 (or PPP1R12C), rAAVs has been eliminated the integrative ability by removal of the rep and cap from the recombinant viral genome, which means rAAVs can not cause insertional mutagenesis resulting from the integration. 3) Like rLVs, rAAVs can infect both dividing and non-dividing cells. 4) rAAVs have several serotypes targeting different specific cell types or tissues. There are multiple methods to produce rAAVs, but typical strategies include helper-free AAV production system and baculovirus-based AAV production system. The helper-free system involves transfecting packaging cells with three different plasmids, 1) vector containing ITR-flanked GOI, 2) vector containing the replication (rep) and capsid (cap) genes, and 3) vector containing essential helper virus genes such as adenovirus E4, E2A and VA. The baculovirus-based AAV production system briefly involves two steps, 1) generation of GOI and helper baculoviruses, 2) co-infection of two baculoviruses into insect cells to achieve rAAVs. The baculovirus-based system is typically used for large scale AAV manufacturing. rAAVs can be divided into different subgroups according to the viral genome and their cap proteins. 1) Numerous AAV serotypes have been identified, but the best characterized is AAV2. So far, almost all rAAVs have utilized ITRs from AAV serotype 2. 2) AAV variants: Single-stranded AAV (ssAAV) & Self-complementary AAV (scAAV) 3) AAV serotypes Related Products: AAV Production Plasmids
For More Readings [1] Douglas M McCarty. Self-complementary AAV vectors; advances and applications. Mol Ther. 2008 Oct;16(10):1648-56. doi: 10.1038/mt.2008.171. PMID: 18682697 DOI: 10.1038/mt.2008.171.[2] Deepak Raj, Andrew M Davidoff, and Amit C Nathwani. Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges. Expert Rev Hematol. 2011 Oct; 4(5): 539–549. doi: 10.1586/ehm.11.48. PMCID: PMC3200187. PMID: 21939421. [3] Anne K Zaiss, Daniel A Muruve. Immune responses to adeno-associated virus vectors. Curr Gene Ther. 2005 Jun;5(3):323-31. doi: 10.2174/1566523054065039. PMID: 15975009 DOI: 10.2174/1566523054065039 [4] Zhijian Wu, Aravind Asokan, R Jude Samulski. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006 Sep;14(3):316-27. doi: 10.1016/j.ymthe.2006.05.009. Epub 2006 Jul 7. PMID: 16824801 DOI: 10.1016/j.ymthe.2006.05.009. [5] Michael F. Naso,corresponding author Brian Tomkowicz, William L. Perry, III, and William R. Strohl. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017; 31(4): 317–334. PMCID: PMC5548848. PMID: 28669112 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Products & Services Resources | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Home Products & Services Support About Us Contact Us |
Promotions Flyers Brochures Publications News & Events |
Terms & Conditions Privacy Disclaimers |
Contact Us EMAIL: admin@rgbiotech.com |
||
© RGBiotech All Rights Reserved. | |||||